The overexpression of cyclooxygenase 2 (COX-2) has been reported in NSCLC.4,5 Increased COX-2 expression is associated with more aggressive tumor behavior and poorer prognosis in patients with NSCLC.6,7,8,9 The rationale for combining a selective COX-2 inhibitor with CCRT was based on the results of preclinical research and nonrandomized clinical studies. The gene discussed is PTGS2; the disease is neoplasm.